{"title": "PDF", "author": "PDF", "url": "www.medigraphic.com/pdfs/vetmex/vm-2006/vm064d.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "441 Vet. M\u00e9x., 37 (4) 2006Producci\u00f3n de vacunas y otros compuestos biol\u00f3gicos \nen plantas transg\u00e9nicas\nProduction of vaccines and other biological compounds \nin transgenic plants\nRecibido el 22 de agosto de 2005 y aceptado el 13 de marzo de 2006.\n*Proyecto de vacunas virales de nueva generaci\u00f3n, Centro Nacional de Investigaciones Disciplinarias en Microbiolog\u00eda Animal, In stituto \nNacional de Investigaciones Forestales, Agr\u00edcolas y Pecuarias, Carretera Federal M\u00e9xico-Toluca, Km 15.5, M\u00e9xico, D. F., 05110, Tel. 5570-\n0616; Fax 5570-4073, correo electr\u00f3nico:   loza.elizabeth@inifap.gob.mx\n**Centro de Investigaci\u00f3n y Estudios Avanzados-Irapuato, Instituto Polit\u00e9cnico Nacional, Km 9.6, Carretera Libramiento Irapuato , Le\u00f3n, \nGuanajuato, M\u00e9xico. Env\u00edo de correspondencia: Elizabeth Loza-Rubio.Abstract\nEven though plants have been utilized by man for medicinal purposes for thousands of years, it is only recently that by using \ngenetic engineering they have been employed as \u201cbiofactories\u201d or \u201cbiorreactors\u201d to produce compounds of pharmaceutical interests. Considering the increased demand for these type of products all over the world, this technology is being increasingl y \nemployed. Nowadays, the high cost of many pharmaceutical compounds limits their distribution and applicability; however, by using  transgenic plants, the cost can be considerably reduced, the product easy to store, production can be scaled up or down,  \nand products will be safer than those produced in other systems. \nKey words:TRANSGENIC PLANTS, EDIBLE VACCINES, ANTIBODIES, BIOREACTORS, PHARMACEUTICAL PRO-\nTEINS. \nResumen\nAunque las plantas se han utilizado durante miles de a\u00f1os con \ufb01  nes medicinales, recientemente comienzan a usarse por medio \nde la ingenier\u00eda gen\u00e9tica  como biof\u00e1bricas o biorreactores con el prop\u00f3sito de producir diversos compuestos de inter\u00e9s farma-\nc\u00e9utico. Como consecuencia de que la demanda  por estos \u00faltimos aumenta en el mundo, el uso de esta tecnolog\u00eda  tambi\u00e9n se \nha extendido. Actualmente el alto costo de muchos compuestos biol\u00f3gicos limita su disponibilidad y aplicaci\u00f3n; en este con-texto, los productos obtenidos de plantas transg\u00e9nicas son, por el contrario, baratos para producir y almacenar, de f\u00e1cil escal a-\nmiento para producci\u00f3n en masa, y m\u00e1s seguros que los derivados de otros sistemas. \nPalabras clave: PLANTAS TRANSG\u00c9NICAS, VACUNAS COMESTIBLES, ANTICUERPOS, BIORREACTORES,  PRO-\nTE\u00cdNAS FARMAC\u00c9UTICAS.Elizabeth Loza-Rubio*       Miguel \u00c1ngel G\u00f3mez-Lim**Art\u00edculos de revisi\u00f3n442Introduction\nThe use of reactors or bioreactors for the indus-\ntrial production of determinate substances is no news. For many years, great quantity of \ndiverse types of compounds (including biologics) in \nother systems have been producing. This was possible because the majority of the genes, of any origin, can be expressed in heterogeneous systems. The ideal expression system would be the one that produces \nthe material in greater quantity, safer and biologically more active at the lowest cost. The use of modi\ufb01  ed \nanimal cells with recombinant DNA techniques has the advantage of producing identical compounds as the naturals; nevertheless, it is highly expensive to cul-ture these cells and it can only be done in a limited \nscale.\n1,2\nThe use of microorganisms, such as bacteria, per-\nmits great scale production, but it has the disadvan-\ntage of originating products that are not equally the \nsame as the ones of natural origin. For instance, pro-\nteins that are generally glycolized  in mammals are not so while being expressed in bacteria. Even more, eukaryotic proteins that express themselves in high levels in Escherichia coli  frequently acquire arti\ufb01  cial \nconformation and are more susceptible to intracellu-\nlar precipitation, due to the lack of disulfur bridges and to an inadequate folding.\n3\nThe \ufb01  rst discovery that allowed the development \no f  b i o t e c h n o l o gy  o f  p l a n t s  i s  t h e  c a p a c i t y  t h a t  o n l y  \none of its cells possesses to originate a complete plant \nwith all the parental characteristics.4,5 The second \ndisc o very was that i t is possi bl e to transf er o nly o n e \ngene to a plant\u2019s genome by the bacterial infection \nof the Agrobacterium tumefaciens.  This has been one of \nthe main methods of genes\u2019 transference to plants. A. \ntumefaciens  carries the plasmid Ti with the concerned \ngene, and as it infects the vegetal cells it transfers the \ngene to the genome of the plant. Other methods of \ntransformation are the microprojectile bombard-ment (biobalistic) and, in lesser grade, the electro-poration.\n5-8\nTh e  m ain  e x p r e ss i o n  p r o m o t e r  us e d  in  p l an ts  is  \nthe 35S of the cauli\ufb02  ower mosaic virus (35S CPMV).9 \nBesides, a series of promoters have been used as con-\nstitutive and tissue speci\ufb01  c, depending on the system \nused and the level of expression desired.10-12 \nThe procedure consists of the concerned gene\u2019s \ninsertion in the adequate  vector that contains the cor-\nrespond promoter and terminator. The vegetal tissue \nthat is going to be utilized may be vegetative (leaves) as well as reproductive (embryos, meristems, pollen, etc.). Once the transformation is done by the mention methods, the vegetal tissue is  incubated in a synthetic \nmedium adequate for the complete plant generation. Introducci\u00f3n \nEl uso de reactores o biorreactores para la pro-\nducci\u00f3n industrial de determinadas sustancias no es nuevo. Durante muchos a\u00f1os se ha pro-\nducido gran cantidad de compuestos de diversos tipos \n(incluyendo los biol\u00f3gicos) en otros sistemas.  Lo ante-rior fue posible debido a que la mayor\u00eda de los genes de cualquier origen se pueden expresar en sistemas heter\u00f3logos. El sistema de expresi\u00f3n ideal ser\u00eda el que \nproduce el material en mayor cantidad, m\u00e1s seguro y biol\u00f3gicamente  m\u00e1s activo con el costo m\u00e1s bajo. De esta manera, el uso de c\u00e9lulas de mam\u00edferos modi\ufb01  ca-\ndas con t\u00e9cnicas de ADN recombinante, tiene la ven-taja de producir compuestos id\u00e9nticos a los naturales; sin embargo, cultivar estas c\u00e9lulas resulta muy costoso \ny se puede realizar solamente en escala limitada.\n1, 2\nEl uso de microorganismos permite la producci\u00f3n \nen escala mayor, pero tiene la desventaja de originar \nproductos que no son exactamente iguales a los de \norigen natural. Por ejemplo, las prote\u00ednas que gene-\nralmente son glicosiladas en mam\u00edferos no lo son al expresarse en bacterias. Adem\u00e1s, las prote\u00ednas euca-riontes que se expresan en altos niveles en Escherichia \ncoli adquieren con frecuencia conformaci\u00f3n arti\ufb01  cial \ny son m\u00e1s propensas a precipitarse en forma intrace-\nlular debido a la carencia de puentes disulfuro y a un plegamiento inadecuado.\n3\nEl primer descubrimiento que permiti\u00f3 el desarro-\nllo de la biotecnolog\u00eda de plantas es la capacidad que \nuna sola de sus c\u00e9lulas posee para originar una planta \ncompleta con todas las caracter\u00edsticas parentales;4,5 el \nsegundo fue que es posible transferir un solo gen al \ngenoma de una planta mediante la infecci\u00f3n bacte-\nriana del Agrobacterium tumefaciens . \u00c9ste ha sido uno \nde los principales m\u00e9todos de transferencia de genes \na las plantas. A. tumefaciens  porta al pl\u00e1smido Ti con el \ngen de inter\u00e9s, de manera que al momento de infectar a las c\u00e9lulas vegetales trans\ufb01  ere el gen al genoma de la \nplanta. Otros m\u00e9todos de transformaci\u00f3n son el bom-\nbardeo de part\u00edculas (biobal\u00edstica) y en menor grado el de electroporaci\u00f3n.\n5-8   \nEl principal promotor de expresi\u00f3n usado en plan-\ntas es el 35S del virus del mosaico de la coli\ufb02  or (35S \nCPMV).9 Adem\u00e1s, se han utilizado una serie de pro-\nmotores tanto constitutivos como espec\u00ed\ufb01  cos de tejido, \nseg\u00fan el sistema utilizado y los niveles de expresi\u00f3n \ndeseados.10-12 \nEl procedimiento consiste en la inserci\u00f3n del gen \nd e  i n t e r \u00e9 s  e n  e l  v e c t o r   a d e c u a d o  q u e  c o n t i e n e  e l  promotor y el terminador correspondiente. El tejido \nvegetal que se va a utilizar puede ser tanto vegetativo (hojas) como reproductor (embriones, meristemos, polen, etc.). Despu\u00e9s de que se efect\u00faa la transforma-ci\u00f3n por medio de dichos m\u00e9todos, el tejido vegetal se 443 Vet. M\u00e9x., 37 (4) 2006In theory, each cell of the new plant should contain a \ncopy of the inserted gene.\nThe production of recombinant proteins in plants \nhas many potential advantages to generate biological compounds of clinical medical importance: a) the veg-\netal systems are more economical than the industrial infrastructure that is based on the use of fermentation or bioreactor systems;\n13 b) the technology to harvest \nand process plants and their by-products at indus-\ntrial scale is available;14-16 c) the puri\ufb01  cation require-\nment of the compound can be eliminated when the plant tissue, that contains the recombinant protein, \nis  us e d  as  f o o d  ( e di b l e  va c cin e ) ;\n17,18 d) the recombi-\nnant proteins can be directed to certain cellular com-\npartments, or directly express them, as in the case of \nchloroplasts;19-21 e) the produced recombinant protein \nimplants can be obtained in industrial scale.22,23\nFinally, the health\u2019s risks that are present by pos-\nsible contamination of the recombinant product with \nhuman pathogens are minimum.9,11 There are two \nareas in which this technology is having an important impact: in the antibodies production and its recep-\ntors, and in the edible vaccine production. \nProduction of antibodies in transgenic \nplants\nFor more than ten years plants have showed to be ver-\nsatile production systems for many forms of antibod-ies like IgG and IgA, IgG/IgA chimerics and others. \nPlants have a great potential as a virtually unlimited \nsource of cheap monoclonal antibodies (called \u201cplan-tibodies\u201d) for human and animal therapy.\n24\nUntil now, the majority of expressed antibodies \nh a v e  b e e n  i n  t o b a c c o ,  a l t h o u g h  p o t a t o ,  s o y ,  a l f a l f a ,  \nrice and wheat have been used.25,26 The principal \nadvantage of using leaves (like tobacco and alfalfa) to produce an antibody, is the ef\ufb01  ciency. Alfalfa, as well \nas tobacco can be harvested several times in a year, \nwith a potential biomass production per year of 17 tons/ha and more than 50 tons/ha, respectively. In contrast, the maximum production of wheat, rice or corn rarely exceeds six tons/ha. Other advantages of \ntobacco are: its facility for genetic manipulation, the production of a great number of seeds (up to one mil-lion per plant) and the need to explore other uses for this crop.\nThe antibodies produced in plants are stable at \nroom  temperatures\n25 as well as 4\u00b0C.27 The vegetal \nmaterial containing the antibody can be stored and \nthe puri\ufb01  cation can be performed in a processing \nplant that does not need to be near the place where \nthe vegetables are and can be used all year. As Table 1 shows, there are many examples of antibodies and its receptors successfully produced in plants; the chime-incuba en un medio sint\u00e9tico adecuado para la gene-\nraci\u00f3n de la planta completa. En teor\u00eda, cada c\u00e9lula de la nueva planta debe contener una copia del gen insertado.  \nLa producci\u00f3n de prote\u00ednas recombinantes en \nplantas tiene muchas ventajas potenciales para gene-rar compuestos biol\u00f3gicos de importancia en medicina cl\u00ednica: a) los sistemas vegetales son m\u00e1s econ\u00f3micos \nque la infraestructura industrial que se basa en el uso de sistemas de fermentaci\u00f3n o en biorreactores;\n13 b) la \ntecnolog\u00eda para cosechar y procesar plantas y sus pro-\nductos a escala industrial ya est\u00e1 disponible;14-16 c) el \nrequisito de la puri\ufb01  caci\u00f3n del compuesto puede ser \neliminado cuando el tejido de la planta, que contiene \nla prote\u00edna recombinante, se utiliza como alimento \n(vacunas comestibles);17,18 d) las prote\u00ednas recombi-\nnantes se pueden dirigir hacia determinados com-\npartimientos celulares, o expresarlos directamente, \ncomo es el caso de los cloroplastos;19-21 e) la prote\u00edna \nrecombinante producida en plantas se puede obtener \na escala industrial.22,23  \nFinalmente, los riesgos a la salud que se presen-\ntan como consecuencia de posible contaminaci\u00f3n del \nproducto recombinante con pat\u00f3genos humanos son \nm\u00ednimos.9,11 Hay dos \u00e1reas en donde esa tecnolog\u00eda \nest\u00e1 teniendo un impacto importan te: en la produc-\nci\u00f3n de anticuerpos y sus receptores, y en la produc-\nci\u00f3n de vacunas comestibles.\nProducci\u00f3n de anticuerpos en plantas\ntransg\u00e9nicas\nDesde hace m\u00e1s de diez a\u00f1os las plantas han demos-\ntrado ser sistemas vers\u00e1tiles de producci\u00f3n para muchas formas de anticuerpos como IgG e IgA, IgG/\nIgA quim\u00e9ricos y otros. Las plantas tienen un gran \npotencial como fuente ilimitada de anticuerpos mono-clonales baratos (llamados \u201cplanticuerpos\u201d) para tera-pia humana y animal.\n24 \nLa mayor\u00eda de los anticuerpos expresados hasta la \nfecha lo han sido en tabaco, aunque tambi\u00e9n se ha \nutilizado papa, soya, alfalfa, arroz y trigo.25,26 La ven-\ntaja principal de usar hojas (como en tabaco y alfalfa) \npara  producir el anticuerpo  es el rendimiento. Tanto \nla alfalfa  como el tabaco pueden ser cosechados varias \nveces al a\u00f1o, con una producci\u00f3n potencial de bio-masa por a\u00f1o de 17 ton/ha y m\u00e1s de 50 toneladas por ha, respectivamente. En contraparte, la producci\u00f3n m\u00e1xima de trigo, arroz o ma\u00edz dif\u00edcilmente rebasa las \nseis ton/ha. Otras ventajas del tabaco incluyen su faci-lidad para manipulaci\u00f3n gen\u00e9tica, la producci\u00f3n de gran n\u00famero de semillas (hasta un mill\u00f3n por planta) y la necesidad de explorar otros usos para este cul-tivo. \nLos anticuerpos producidos en plantas son estables 444ric   secretor antibody of IgG/IgA against a super\ufb01  cial \nantigen of Streptococcus mutans , causal agent of dental \ncavities, tested inclusive in humans and produced in \ntobacco, was applied topically to several volunteers\u2019 \nteeth and was found to be as effective as a IgG pro-duced in mouse hybridoma to prevent the re-coloni-zation of th e gums by S, mutans .\n28 Another example \nis the antibody against the herpes (HSV) virus pro-\nduced in soy and resulted ef\ufb01  cient in the prevention \nof the vaginal infection by HSV in mouse.29\nAn important aspect that has been outstanding \nin the production of antibodies in plants is the low production cost potential. There are few  cost studies; \ntherefore, the available estimations imply some sup-\npositions. The cost of producing IgG in alfalfa grown in a greenhouse of 250 m\n2 was estimated in 500-600 \ndollars per gram, compared to 5000 dollars per gram \nfor the same antibody produced in hybridomes.13 It is \nunquestionable that the levels of expression will have a signi\ufb01  cant impact on costs. The highest level of expres-\nsion registered for a plantibody was for a secreted IgA \n(500 \u00b5g/g of leaf),\n26 with a \ufb01  nal cost estimated below \n50 dollars per gram. This contrasts with the costs of a \npuri\ufb01  ed antibody, obtained from a cell culture (one tanto a temperatura ambiente25 como a 4\u00baC.27 El mate-\nrial vegetal que contiene al anticuerpo se puede alma-cenar y as\u00ed la puri\ufb01  ca ci \u00f3 n  s e  p u e d e  r e alizar  e n  un a  \nplanta de procesamiento que no necesita estar cerca \ndel lugar donde est\u00e1n los vegetales, adem\u00e1s se puede  \nutilizar todo el a\u00f1o. Como muestra el Cuadro 1, hay muchos ejemplos de anticuerpos y sus receptores pro-ducidos exitosamente en plantas; en este sentido, el \nanticuerpo secretor quim\u00e9rico de IgG/IgA contra un ant\u00edgeno super\ufb01  cial de Streptococcus mutans , agente \ncausal de la cari es den tal, se ha pro bado in cl uso en humanos dicho anticuerpo, producido en tabaco, se aplic\u00f3 t\u00f3picamente a los dientes de varios voluntarios y se encontr\u00f3 que era tan e\ufb01  caz como una IgG produ-\ncida en un hibridoma de rat\u00f3n para prevenir la reco-lonizaci\u00f3n de las enc\u00edas por S. mutans .\n28 Otro ejemplo \nes el anticuerpo contra el virus  del herpes (HSV) que \nfue producido en soya y result\u00f3 e\ufb01  caz en la prevenci\u00f3n \nde la infecci\u00f3n vaginal por HSV en rat\u00f3n.29 \nUn aspecto importante que se ha destacado de la \nproducci\u00f3n de anticuerpos en plantas se re\ufb01  ere al \nbajo costo de producci\u00f3n. Existen pocos estudios de \ncostos y por eso las estimaciones disponibles implican algunas suposiciones. Por ejemplo, el costo de produ-\n \nPLANTICUERPOS PARA USOS TERAP\u00c9UTICOS Y DE DIAGN\u00d3STICO  \nPLANTIBODIES FOR THERAPEUTIC  AND DIAGNOSIS USES \nApplication and  \nspecificity  \nAntibody type  \nPlant  \nExpression levels  \nRefs \n \nDental cavities; \nAntigen I or II of \nS.mutants  IgA Nicotiana \ntabacum  500 \u00b5g/g leaves fresh \n(FW) weight 70,71 \nDiagnosis;anti-human \nIgG  IgG Alfalfa 1.0% Total soluble \nprotein (TSP) 13 \nCancer treatment; \ncarcinoembryonic \nantigen Simple chainfrom \nantibody FvScFv Wheat 900.0 \u00b5g/g leaves 1.5  \n\u00b5g/g seeds 25 \nCancer treatment; \ncarcinoembryonic \nantigen ScFv Rice 29.0 \u00b5g/g leaves; \n32.0 \u00b5g/g seeds; 3.8 \u00b5/g \ncallous 25 \nCancer treatment; \ncarcinoembryonic \nantigen ScFv Rice 27.0 \u00b5g/g leaves 25 \nCancer treatment: \ncarcinoembryonic \nantigen IgG Nicotiana tabaccum 1.0 \u00b5g/g leaves  32 \nB cells lymphoma \ntreatment; ideotype \nvaccine scFv Nicotiana benthamiana 30.0 \u00b5g/g leaves 74 \nHerpes simples virus 2 IgG Soy Not informed (NI) 29 \nB Hepatitis Surface Anti-antigen \nof Hepatitis B Nicotiana tabacum Variable 15-40 \u00b5g/g 23 \nAnti RH Factor Anti RH-D Arabidopsis NI 73 \nAntirabies treatment IgG Nicotiana tabacum NI 74 \nPolyepitope of cells B \nagainst measles  scFv Carrot  NI 75 Cuadro 1445 Vet. M\u00e9x., 37 (4) 2006cir IgG en alfalfa crecida en un invernadero de 250 \nm2 se estim\u00f3 en 500-600 d\u00f3lares por gramo, en com-\nparaci\u00f3n con los cinco mil d\u00f3lares por gramo para \nel mismo anticuerpo producido en hibridomas.13 Es \nindudable que los niveles de expresi\u00f3n tendr\u00e1n un impacto signi\ufb01  cativo en los costos. El nivel de expre-\nsi\u00f3n m\u00e1s alto registrado  para un planticuerpo ha sido \npara una IgA secretada (500 \u00b5g/g de hoja),\n26 cuyo \ncosto \ufb01  nal se estim\u00f3 inferior a 50 d\u00f3lares por gramo. \nEsto \u00faltimo contrasta con los costos de un anticuerpo \npuri\ufb01  cado, obtenido en  cultivo de c\u00e9lulas (mil d\u00f3la-\nres/g), o a partir de animales transg\u00e9nicos (100 d\u00f3la-\nres/g). El costo m\u00e1s relevante en la obtenci\u00f3n  de  \nplanticuerpos se observa en el proceso de puri\ufb01  ca-\nci\u00f3n. Sin embargo, la expresi\u00f3n en g\u00e9rmenes de arroz \ny trigo.25 plantea la posibilidad de la administraci\u00f3n \noral de algunos anticuerpos terap\u00e9uticos sin necesi-\ndad de la puri\ufb01  caci\u00f3n, ya que las plantas transforma-\ndas pueden administrarse directamente por v\u00eda oral, \ncomo consecuencia del sistema inmune de la mucosa intestinal que permite el reconocimiento y absorci\u00f3n de diversas mol\u00e9culas. Debido a esto \u00faltimo, cada vez se producen m\u00e1s prote\u00ednas recombinantes  con dife-\nrentes prop\u00f3sitos (Cuadro 2).\n22,30 \nMuchos anticuerpos est\u00e1n  sujetos a un proceso  de thousand dollars/g), or from transgenic animals (100 dollars/g). The most relevant cost in the obtainment of plantibodies is the puri\ufb01  cation. Nevertheless, the \nexpression in rice and wheat germs\n25 opens the pos-\ns i b i l i t y  o f  o r a l  a d m i n i s t r a t i o n  o f  s o m e  t h e r a p e u t i c  \nantibodies without the necessity of puri\ufb01  cation, since \nthe transformed plants can be administered directly \nper oral, as a consequence of the intestinal mucous\u2019 immune system that allows the recognition and absorption of diverse molecules. Due to the former, more recombinant proteins are being produced with \ndifferent purposes (Table 2).\n22,23 \nMany antibodies are subjected to glycosylation, \nwhich is critical for it\u2019s activity. There is a study that \nanalyzes the glycosylation of an  antibody produced in \nplants in comparison to the one produced on hybrid-omes of mouse.\n31 It was found that sugars in the anti-\nb o d y  d e r i v e d  f r o m  p l a n t s  w e r e  s t r u c t u r a l l y  d i v e r s e ;  \n40% was mannose type. Other 60% had  type \u00df-(1,2)-\nxylose and \u00df-(1,3)-fucose links. These links are typical \nof plants, but are not found in mammals. The sialic acid, that represented 10% of the sugar content of the monoclonal antibody of the mouse, was not found in the antibodies of plants. Nevertheless, these struc-\ntural differences seemed not to have any effect over \nCuadro 2  \nPROTE\u00cdNAS DE IMPORTANCIA  TERAPEUTICA PRODUCIDAS  \nEN PLANTAS TRANSG\u00c9NICAS  \nIMPORTANT THERAPEUTIC PROTEINS PR ODUCED IN TRAN SGENIC PLANTS \nAplication or potential \nuse  \nProtein \n  \nPlant  \nExpression level  \nRefs \nNeutropenia  Human GM-CS factor Tobacco Not informed (NI) 85 \nGrowth hormone  Human somtotropin Tobacco 7.00% TSP 19 \nGrowth hormone Nuclear expression Tobacco < 0.01% TSP  19 \nAnemia Human erythropoietin Tobacco < 0.01% TSP  14 \nAntihyperanalgesic Human encephalin Arabidopsis 0.10% protein of seed  14 \nTreatment for Hepatitis \nC and B Human interpheron-\u03b2 Tobacco < 0.01% fresh weight  14 \nHepatic cirrhosis, \nburns,surgery Human serum albumin  Tobacco 0.02% TSP 14 \nCollagen Human homotrimetric \ncollagen Tobacco < 0.01% fresh weight  86 \nCystic fibrosis,hepatic \ndiseases and \nhaemorrhage Human \u03b1 \u2013 1-\nantitrypsin Rice NI 85 \nTrypsin inhibitor for \ntransplant surgery Human aprotinine  Corn NI 85 \nAntimicrobiotic Human lactoferrin Potato 0.10% TSP 87 \nHypertension Angiotensin converter \nenzyme Tobacco, tomato NI 85 \nHIV-AIDS therapy \u03b1-Tricosanthin \nofTMV-U1 Protein of \nthe subgenomic capsid Nicotiana bethamiana 2.00% TSP 85 \nVacunal \nadjuvant,therapy \nagainst cancer IL-12 Tobacco NI 88 446the union to the antigen or the af\ufb01  nity in vitro13,26,29,32 \nand could be insigni\ufb01  cant in vivo . A IgG produced in \nalfalfa had a middle life in serum of Balb/c mice simi-\nlar to that of a monoclonal antibody (MA).13\nAlthough there has been certain concern for the \nimmunogenicity potential and allergenic capacity of the plantibodies, maybe these will not present any \nproblems for the majority of individuals because the \nglycoproteins of plants are ubiquitous in the human and animal diet.\n33 In this sense, there was no evidence \nof allergic reaction to a anti-mouse human antibody \nin 60 patients that received the topic oral application \nof speci\ufb01  c secretor IgA  for S. mutans .28 \nEdible vaccines\nThe production of diverse antigens in transgenic \nplants is a demonstrated fact throughout the years.34  \nThe interest to perform these experiments aroused due to the uncertainty that some immunogenic pro-teins could be synthesized in plants and later use the \nvege tal tissue as oral imm un ogens in h uman beings \nor animals. Currently,  it has been demonstrated that this idea is totally viable using diverse bacterial and viral proteins.\nVaccination in great scale faces a series of dif\ufb01  -\nculties; on one side, the high costs of vaccines  and, \non the other, the risk that the distribution in remote places and of dif\ufb01  cult access, might not be adequate. \nThe World Health Organization has recommended the search for options to substitute injections, due to the fact that in some countries up to 30% of these are \ndone with syringes that are not sterile because of eco-\nnomical problems in those places. In this context, the oral administration would be a good alternative for the vaccines that are actually administered parenterally.  \nWith oral vaccines the probability of acquiring immu-nity  through the mucous against infectious agents that enter the body by this route is incremented.\n35 \nAn important worry about oral vaccines is the deg-\nradation of the antigens in the stomach and intestine \nbefore they can induce an immune response. To pro-\ntect them from degradation, several methods have been developed, like the use of recombinant strains of attenuated microorganisms (for instance, Salmonella ) \nof bio-encapsulation vehicles, like liposomes, and \n\ufb01 nally transgenic plants.\nIn theory, the ideal species to express the anti-\ngens should be consumed fresh and have high levels o f  s o l u b l e  p r o t e i n ;  i n  t h i s  s e n s e ,  f r u i t s  l i k e  b a n a n a  and tomato or cereals, are convenient systems for this p u rp o s e .  Al th o u g h  i n  th e  \ufb01  rst studies with vaccines \nderived from plants, tobacco and potato were used, due to its facility of manipulation.\n36-39\nTable 3 shows the variety of antigens of human glicosilaci\u00f3n,  lo cual es cr\u00edtico para su actividad. En \nesta tesitura, existe un estudio  que analiza la glico-silaci\u00f3n  de un anticuerpo producido en plantas en \ncomparaci\u00f3n con el que se produce en hibridomas \nde rat\u00f3n.\n31 Se  e n c o n tr \u00f3  q u e  l o s  az\u00fa c ar e s  e n  e l  an ti-\ncuerpo derivado de plantas eran estructuralmente \nm\u00e1s diversos; 40% fue del tipo manosa, otro 60% \nten\u00eda enlaces tipo \u00df-(1,2)-xilosa y \u00df-(1,3)-fucosa. Estos \nenlaces son t\u00edpicos de plantas, pero no se encuentran en mam\u00edferos. El \u00e1cido si\u00e1lico, que representaba 10% del contenido de az\u00facar del anticuerpo monoclonal de rat\u00f3n, no se encontr\u00f3 en el anticuerpo de plantas. \nSin embargo, estas diferencias en estructura parecie-ron  no tener efecto sobre la uni\u00f3n al ant\u00edgeno o sobre la a\ufb01  nidad in vitro .\n13,26,29,32 y pudieran ser intrascen-\ndentes in vivo. Un IgG producido en alfalfa tuvo vida \nmedia en suero de  ratones Balb/c, similar a la de un \nanticuerpo monoclonal (AM).13  \nAunque ha habido cierta preocupaci\u00f3n por la \ninmunogenicidad  potencial y capacidad alerg\u00e9nica de los planticuerpos, quiz\u00e1 \u00e9stos no presenten proble-\nmas para la mayor\u00eda de los individuos porque las glico-prote\u00ednas de plantas son ubicuas en la dieta humana y animal.\n33 En este sentido, no hubo evidencia de reac-\nci\u00f3n al\u00e9rgica a un anticuerpo humano antirrat\u00f3n en \n60 pacientes que recibieron la aplicaci\u00f3n oral t\u00f3pica \nde IgA secretora espec\u00ed\ufb01  ca  para S. mutans .28 \nVacunas comestibles \nLa producci\u00f3n de diversos ant\u00edgenos en plantas trans-\ng\u00e9nicas constituye un hecho demostrado desde hace a\u00f1os.\n34 El inter\u00e9s para realizar estos experimentos \nsurgi\u00f3 debido a la duda sobre si determinadas prote\u00ed-nas inmunog\u00e9nicas se podr\u00edan sintetizar en plantas, \ny despu\u00e9s usar el tejido vegetal como inmun\u00f3genos \norales en seres humanos o en animales. Actualmente se ha demostrado que esta idea es viable si se utilizan diversas prote\u00ednas bacterianas y virales. \nLa vacunaci\u00f3n en gran escala enfren ta una serie \nde di\ufb01  cultades; por un lado, los altos costos de las \nvacunas y, por otro, el riesgo de que la distribuci\u00f3n en \nlugares remotos y de dif\u00edcil acceso no sea adecuada. L a  O r g a n i z a c i \u00f3 n  M u n d i a l  d e  l a  S a l u d  h a  r e c o m e n -d a d o  l a  b \u00fa s q u e d a  d e  o p c i o n e s  p a r a  s u s t i t u i r  a  l a s  inyecciones, debido a que ha encontrado que en algu-\nnos pa\u00edses hasta 30% de \u00e9stas se realizan con jeringas \nno est\u00e9riles, debido a los problemas econ\u00f3micos de esos lugares. En este contexto, la aplicaci\u00f3n  oral ser\u00eda buena alternativa para las vacunas que actualmente se administran v\u00eda parenteral. Con las vacunas orales se incrementa la probabilidad de adquirir inmunidad en mucosas contra agentes infecciosos que entran al cuerpo a trav\u00e9s esta ruta.\n35  \nU n a  p r e o c u p a c i \u00f3 n  i m p o r t a n t e  r e s p e c t o  d e  l a s  447 Vet. M\u00e9x., 37 (4) 2006pathogens expressed in transgenic plants. The anti-\ngens derived from plants have induced immune response at mucous and serum level, when they have \nbeen administered by injections as well as per oral in \nlaboratory animals. Several experiments exist where these have adequately protected against the patho-gen.\n10,36-44 Likewise, several clinical tests have been suc-\ncessfully performed with human volunteers where the \norally consumed antigens, in vegetal tissue, induced \na signi\ufb01  cant immune response.45-50 For this reason, \nit is considered that prepared vaccines in plants have \ngreat potential.51 The bio-encapsulation of the B sub-\nunit of the labile toxin of Escherichia coli  in transgenic \ncorn, induced a strong immune response in mice, in \ncomparison to the one reached by the sole antigen, \nwhich was weaker.49 Maybe this was due to the fact that \nthe antigen was protected against degradation in the \nintestine.\nConsidering the serious problem of pathogens that \naffect public health like: AIDS, hepatitis B, anaplas-\nmosis, malaria and rabies, among others, this fact is of great relevance.\nEdible vaccines in veterinary \ufb01  eld\nThere are several reports on edible vaccines against \ndiseases that affect animals (Table 4) which have been evaluated in laboratory and domestic animals. Since \n1996, it has been reported that antigens and protector \npeptides expressed in plants of Arabidopsis, tobacco, potato, corn and peanut, have been tested in labora-tory animals and pigs.\n49,52,53 So m e  o f  th e  e di b l e  va c-\ncines of veterinary interest that have been obtained in \nplants have expressed for example: glycoprotein S and \nprotector peptides of the coronavirus which produce \ntransmissible gastroenteritis in pigs (TGE); peptides of the VP2 from canine parvovirus; the VP1 from foot and mouth disease ; the VP60 from the virus that pro-duce the hemorrhagic rabbit disease, a lineal peptide \nof the hemagglutinin of the rinderpest virus and a gene that codi\ufb01  es for a virulence factor (F18) of E. \ncoli t h a t  p r o d u c e s  s w i n e  o e d e m a .\n15,42,54,55 Likewise, \na peptide has been selected that possesses the same \nsequence of protector peptides that are found in the \nmink enteritis virus, canine parvovirus and feline pan-\nleukopenia. This protein fragment expressed itself in the cauli\ufb02  ower mosaic virus, the authors proposed \nthat this construction could protect against these three diseases.\n56 All these tests report parenteral adminis-\ntration (injection) of the puri\ufb01  ed proteins, or orally \nconsuming fresh plants. For both routes, immunoglob-\nulins (Ig) G, IgA were promoted, and in the case of \nevaluating the protection, it was always reported to be more than 80%. In 1999, it was reported that the use of  protein VP1 of the aphthous fever, using as a vector vacunas orales es la degradaci\u00f3n de los ant\u00edgenos en \nel est\u00f3mago e intestino antes de que puedan inducir una respuesta inmune. Para proteger a aqu\u00e9llos de la degradaci\u00f3n, se han desarrollado varios m\u00e9todos, como  el uso de cepas recombinantes de microorga-nismos atenuados ( v. gr., Salmonella ), o de veh\u00edculos \nde bioencapsulaci\u00f3n, como liposomas, y \ufb01  nalmente la \nutilizaci\u00f3n de plantas transg\u00e9nicas. \nEn teor\u00eda, la especie ideal para expresar los ant\u00edge-\nnos deber\u00eda consumirse en fresco y tener altos niveles d e  p r o t e \u00ed n a  s o l u b l e;  e n  e s t e  s e n ti d o ,  fru t o s  c o m o  e l  pl\u00e1tano y el jitomate o los cereales, son sistemas conve-nientes para este \ufb01  n; aunque en los primeros trabajos \ncon vacunas derivadas de plantas se us\u00f3 tabaco y papa, debido a la facilidad de su manipulaci\u00f3n.\n36-39 \nEl Cuadro 3 ilustra la variedad de ant\u00edgenos de \npat\u00f3genos humanos expresados en  plantas transg\u00e9ni-\ncas. Los ant\u00edgenos derivados de plantas han inducido \nrespuestas inmunes a nivel de mucosas y de suero, cuando han sido administrados tanto con inyecciones c o m o  po r  v\u00eda  o ral  e n  animal es  d e  la bo ra to ri o .  Exis-ten varios experimentos donde \u00e9stos han protegido \nadecuadamente contra el pat\u00f3geno.\n10,36-44 Asimismo, \nse han realizado exitosamente varias pruebas cl\u00ednicas \ncon voluntarios humanos; se observ\u00f3 que los ant\u00edge-\nnos consumidos v\u00eda oral en tejido vegetal indujeron \nrespuesta inmune signi\ufb01  cativa.45-50 Por esta raz\u00f3n \nse considera que las vacunas preparadas en plantas \ntienen gran potencial.51 La bioencapsulaci\u00f3n de la \nsubunidad B de la toxina l\u00e1bil de Escherichia coli e n \nma\u00edz transg\u00e9nico indujo fuerte respuesta inmune \nen ratones, en comparaci\u00f3n con la alcanzada con el \nant\u00edgeno desnudo, que fue m\u00e1s d\u00e9bil.49 Quiz\u00e1 esto \nse debi\u00f3 a que el ant\u00edgeno estaba protegido contra la \ndegradaci\u00f3n en el intestino. \nDe acuerdo con lo anterior, al considerar el grave \nproblema de pat\u00f3genos que afectan la salud p\u00fablica, \ncomo el sida, hepatitis B, anaplasmosis, malaria y rabia, entre otros, el planteamiento que se hace en este trabajo es de gran relevancia. \nVacunas comestibles en el campo\nveterinario \nExisten varios informes sobre vacunas comestibles \ncontra enfermedades que afectan a los animales (Cuadro 4), aqu\u00e9llas ya han sido evaluadas tanto en \nanimales de experimentaci\u00f3n como en  animales de \ncompan\u00eda. A partir de 1996 se ha informado respecto de ant\u00edgenos y p\u00e9ptidos protectores expresados en plantas de Arabidopsis, tabaco, papa, ma\u00edz y caca-huate, que se han usado en animales de laboratorio \ny en cerdos.\n49,52,53 Algunas de las vacunas comestibles \nde inter\u00e9s veterinario obtenidos en plantas se han \nexpresado de la siguiente manera: la glicoprope\u00edna S 448the mosaic virus of tobacco, produces protection in \nmice.10 Afterward, experiments have been performed \nto characterize the imm une response provoked by a chimeric plant against canine parvovirus that induces \nmucous and systemic immunity in mice.\n57\nIn the zoonosis \ufb01  eld, the G protein as well as the \nN of the rabies virus have been expressed in several y p\u00e9ptidos protectores del coronavirus, \u00e9sta produce \nla gastroenteritis transmisible de los cerdos (GETC); los p\u00e9ptidos de la VP2 del parvovirus canino, la VP1 de la \ufb01  ebre aftosa; la VP60 del virus que produce la \nenfermedad hemorr\u00e1gica de los conejos, un p\u00e9ptido \nlineal de la hemaglutinina del virus de rinderpest y un gen que codi\ufb01  ca para un factor de virulencia (F18) de Cuadro 3  \nANT\u00cdGENOS DE PAT\u00d3GENOS HUMANOS, EX PRESADOS EN PLANTAS TRANSG\u00c9NICAS  \nHUMAN PATHOGEN ANTIGENS, EXPR ESSED IN TRANSGENIC PLANTS  \nExpressed protector \nantigen  \nCausal agent  \nPlant  \nExpression level  \nImmunogenic capacity  \nRefs \n \nSubunit B of the \nheat sensible toxin E. coli  \nenterotoxigenic Tobacco < 0.01%Total soluble \nprotein (TSP) The intact protein \nforms multimerics and \nis immunogenic \nadministered  orally 36 \nSubunit B of the \nheat sensible toxin E. coli  \nenterotoxigenic Potato 0.19% TSP Immunogenic, \nprotector and of \nbinding activity \nadministered  orally 36,43,45 \nSubunit B of the \nheat sensible toxin E. coli  \nenterotoxigenic Corn Not informed (NI) Immunogenic and \nprotector administered  \norally 49 \nSubunit B of the \nheat sensible toxin Vibrio cholerae Potato 0.30% TSP The intact protein \nforms multimerics, has \nthe activity of binding \nto the receptor and it is \nimmunogenic and \nprotector administered  \norally 40, 64 \nMain antigen Anthrax Tobacco NI Biological activity 76 \nSuperficial protein \nof the cover Hepatitis B virus Potato < 0.01% Fresh \nweight (FW) Forms virus type \nparticles and the \nextracted protein is \nimmunogenic \nadministered \nparenterally  37, 44 \nSuperficial protein \nof the cover Hepatitis B virus Lupine \n(Lupinus  spp) > 0.01% FW  Immunogenic \nadministered orally 65 \nSuperficial protein \nof the cover Hepatitis B virus  > 0.01% FW  Immunogenic \nadministered orally 46 \nProtein of the capsid Norwalk virus Tobacco 0.23% TSP Forms virus type \nparticles, immunogenic \nadministered orally 38 \nProtein of the \ncapsid Norwalk virus Potato 0.37% TSP Forms virus type \nparticles, immunogenic \nadministered orally 38,67 \nGlycoprotein Rabies virus Tomato  1.00% TSP Intact protein  39 \nGlycoprotein B Human \ncytomegalovirus Tobacco < 0.02% TSP  Immunologically \nrelated protein 66 \nProtein F Respiratory syncytial \nvirus Tomato NI Immunogenic \nadministered orally 78 \nHPV 11 Papillomavirus Potato NI Immunogenic \nadministered  orally 79 \nPrinciple protein of \nthe capsid L 1 Papillomavirus Norwalk virus 0.2% - 0.5% TSP Immunogenic \nadministered  orally 80 \nHPV type 16 \u2013 L 1 Papillomavirus Nicotiana \ntabacum 0.2% - 0.4% FW Immunogenic \nadministered  orally 81 \nVP 7 Rotavirus Potato NI Immunogenic \nadministered  orally 80 449 Vet. M\u00e9x., 37 (4) 2006vegetables, and several tests have been done in mice \nand humans;39,50,58 nevertheless, few tests are done to \nproduce an edible vaccine against bovine rabies, dis-\nease that in Latin America causes severe economical \nlosses.59 \nPresently, different groups are working in this area \ntrying to speci\ufb01  cally induce an immune response of \ncellular type,  using as adjuvants cytokine and chem-\nokine molecules. This strategy has been used60-62 \nalthough not with  plants administered orally, but \nparenterally. Thus, it is expected not only to induce a general immunity, but to in\ufb02  uence on the type of \nresponse. Besides, it has been recently determined \nthat the DNA of plants possesses immunostimulatory sequences, since it was proved that the DNA of plants can activate the antigen-presenting cells, including dendritic cells, macrophages and B cells, for which \nthey are considered as potential adjuvant.\n63\nE x p r e s s i o n  l e v e l s  o f  b i o - p h a r m a c e u t i c a l  \ncomponents in transgenic plants\nThe quantity of vegetal tissue that constitutes a dose \nof vaccine should be small. For this, it is important to reach high levels of protector antigen expression in \nthe vegetal tissue. Different strategies have been used \nto increase the levels of expression of the transgenes; E. coli que produce el edema de los cerdos.\n15,42,54,55 Asi- \nmismo, se ha elegido un p\u00e9ptido que posee la misma \nsecuencia de p\u00e9ptidos protectores que se encuentran \nen los virus de enteritis del mink, parvovirus canino \ny panleucopenia felina. Este fragmento de prote\u00edna se expres\u00f3 en el virus del mosaico de la coli\ufb02  or, los \nautores propusieron que esta construcci\u00f3n podr\u00eda proteger contra estas tres enfermedades.\n56 Todos \nestos ensayos noti\ufb01  can la administraci\u00f3n, v\u00eda paren-\nteral, de las prote\u00ednas puri\ufb01  cadas, o bien por v\u00eda oral \ncomiendo las plantas frescas. Por ambas rutas se han promovido inmunoglobulinas (Ig) G, IgA y, en caso de haber evaluado la protecci\u00f3n, se informa que \u00e9sta fue  siempre m\u00e1s de 80%. En 1999 se noti\ufb01  c\u00f3 que el \nuso de la prote\u00edna VP1 del virus de la \ufb01  ebre aftosa, \nusando como vector al virus del mosaico de tabaco, \nproduce protecci\u00f3n en ratones.\n10  Posteriormente se \nhan realizado experimentos para caracterizar la res-\npuesta inmune provocada por una planta quim\u00e9rica \ncontra el parvovirus canino, que induce inmunidad \nmucosal y sist\u00e9mica en ratones.57  \nEn el campo de las zoonosis, tanto la prote\u00edna G \ncomo la N del virus de la rabia se han expresado en \ndiversos vegetales; en este sentido,  se han realizado \nvarios ensayos en ratones y en humanos;39,50,58 sin \nembargo, en la actualidad apenas se realizan ensayos \npara producir una vacuna comestible contra la rabia  \nANT\u00cdGENOS DE PAT\u00d3GENOS ANIMALES  EX PRESADOS  EN PLANTAS TRANSG\u00c9NICAS  \nANTIGENS OF ANIMAL PATHOGENS EX PRESSED IN TRANSGENIC PLANTS \n \nCausal agent  Protector antigen \nexpressed in plants   \nPlant   \nExpressed level   \nImmunogenic capacity   \nRefs \n \nHemorrhagic virus \nof rabbits VP60 Potato 0.30% TSP Immunogenic and \nprotector administered \norally 47, 83 \nFoot and mouth \ndisease VP1 Arabidopsis NI Immunogenic and \nprotector administered \norally Norwalk virus \nFoot and mouth \ndisease VP1 Alfalfa NI Immunogenic and \nprotector administered  \norally 10 \nFoot and mouth \ndisease Epitope highly \nimmunogenic \nVP135 - 160 Alfalfa NI Immunogenic and \nprotector administered \norally  54 \nFoot and mouth \ndisease VP1 Tobacco NI Immunogenic and \nprotector administered \norally 84 \nTransmissible \ngastroenteritis in \npigs (TGE)  Glycoprotein S Arabidopsis 0.06% TSP Immunogenic and \nprotector administered \nparentarally 42 \nTGE Glycoprotein S Corn < 0.01% FW  Protector per oral 49 \nRinderpest virus Hemagglutinin Peanut NI Seroconversion when \nadministered \nparenterally with plant \nderivatives 53 Cuadro 4450for instance, utilizing diverse regulation signals of \nthe genetic expression, as well as optimizing the use of codones.\n43,48,49 The levels of expression could rise \nthrough the cross of transformed lines with estab-lished and well characterized  lines, this strategy has \nbeen applied with success to increase the total pro-\ntein production in corn. It is important that any anti-gen is present in its natural form in the vegetal tissue, this is evaluated as the size of the synthesized protein examined, its capacity to form adequate structures \n(for instance, virus type particles) and demonstrating enzymatic activity or union to a receptor.\n10,36,38,39,43,48,64 \nThe stability of the heterologous  proteins and the \na s s e m b l e  o f  m u l t i m e r i c  s t r u c t u r e s  d e p e n d  o n  t h e  \nsubcellular  location. Until now, the principle places \nwhere antigens have been expressed are the cellular surface, endoplasmic reticulum and Golgi appara-tus. \n36,48,64-66 In spite of some reports on high levels of \nexpression, there is a great necessity to \ufb01  nd mecha-\nnisms to increase the antigen expression in plants and \nallow its commercial production in great scale. For \nthat purpose, a strategy that has been lately followed  \nis the fusion of antigenic peptides to the \u00df-glucuro-nidase protein GUS), with which the expression that normally was of 0.01% to 0.2% can increase up to 3% \nof the total soluble protein; it has also been used the transformation of plants via chloroplasts and it has b e e n  p u b l i s h e d   t h a t  l e v e l s  o f  e x p r e s s i o n  o f  a l m o s t  2.5% of the total soluble protein of the plant may be obtained.\n21 \nIn general, the levels of expression of the proteins \nwith pharmaceutical application produced in trans-\ng e n i c  p l a n ts  h a v e  b e e n  o f  l e s s  th a n  1 %  o f  th e  t o tal  \nsoluble protein. This limit of 1% is important for a possible commercial application, if the protein must be puri\ufb01  ed.\n14 The surface antigen of the hepatitis B \ninduced only a low level response in serum antibodies \nin a study on human volunteers, this may re\ufb02  ect the \nlow level of expression (1-5 ng/g of fresh weight) in \ntransgenic lettuce.46 Although the protein of the cap-\nside of the Norwalk virus expressed in potato induced \nimmunization when consumed orally, the levels of the \nexpression were low for the oral administration in \ngreat scale: 0.37% of total soluble protein (TSP).38,67 \nThe expression of the genes that codify for other \nh u m a n  p r o t e i n s  i n  t r a n s g e n i c  p l a n t s  h a s  a l s o  b e e n  \nlow: human serum albumin, 0.020% TSP; erythropoi-\netin, ~0.003% TSP; human-\u00df interferon, <0.01% TSP.\nFuture perspectives \nRecently, different groups are working in this area \ntrying to speci\ufb01  cally induce an immune response of \ncellular type, using as adjuvants cytokine and chimok-\nine molecules.60-62 Therefore, it is expected not only bovina, padecimiento que en Am\u00e9rica Latina causa \nseveras p\u00e9rdidas econ\u00f3micas.59\nHoy d\u00eda,  diferentes grupos trabajan en esta \u00e1rea \npara intentar inducir una respuesta inmune de tipo \ncelular espec\u00ed\ufb01  ca, utilizando como adyuvantes mol\u00e9-\nculas de citocinas y quimiocinas. Esta estrategia se \nha empleado60-62 aunque no con plantas ni por v\u00eda \noral, sino v\u00eda parenteral. As\u00ed, se espera no s\u00f3lo indu-\ncir una inmunidad general, sino tambi\u00e9n in\ufb02  uir en el \ntipo de respuesta. Aunado a ello, recientemente se ha \ndeterminado que el ADN de plantas posee secuencias inmunoestimulatorias, ya que se comprob\u00f3 que este \u00faltimo puede activar a las c\u00e9lulas presentadoras de ant\u00edgeno, incluyendo c\u00e9lulas dendr\u00edticas, macr\u00f3fagos \ny c\u00e9lulas B, por lo que se le considera como adyuvante potencial.\n63 \nNiveles de expresi\u00f3n de compuestos biofar-\nmac\u00e9uticos en plantas transg\u00e9nicas \nLa cantidad de tejido vegetal que constituya una dosis \nde vacuna debe ser peque\u00f1a. P or ello es importante alcanzar altos niveles de expresi\u00f3n del ant\u00edgeno pro-\ntector en el tejido vegetal. Se han utilizado diferentes \nestrategias para aumentar los niveles de expresi\u00f3n de los transgenes; por ejemplo, utilizando diversas se\u00f1a-les de regulaci\u00f3n de la expresi\u00f3n gen\u00e9tica, as\u00ed como al optimizar el uso de codones.\n43,48,49 Los niveles de \nexpresi\u00f3n se podr\u00edan elevar a trav\u00e9s de cruzas de l\u00edneas \ntransformadas con l\u00edneas establecidas y bien caracte-\nrizadas; esta estrategia se ha aplicado con \u00e9xito para \naumentar la producci\u00f3n de prote\u00edna total en ma\u00edz. Es importante que cualquier ant\u00edgeno est\u00e9 presente en s u  f o rm a  n a tu ral  e n  e l  t e j i d o  v e g e tal ,  e l l o  s e  e val \u00fa a  al examinar el tama\u00f1o de la prote\u00edna sintetizada, su \ncapacidad de formar las estructuras adecuadas (por ejemplo, part\u00edculas tipo virus) y demostrando activi-dad enzim\u00e1tica o de uni\u00f3n a un receptor.\n10,36,38,39,43,48,64 \nLa estabilidad de las prote\u00ednas heter\u00f3logas y el ensam-\nblaje de estructuras multim\u00e9ricas dependen de la \nlocalizaci\u00f3n subcelular. Hasta ahora, los principales \nlugares en donde se han expresado ant\u00edgenos son la super\ufb01  ci e c e l ular , e l re t\u00ed cul o e n d o pl\u00e1smi c o y e l apa-\nrato de Golgi.\n36,48,64-66 A pesar de algunos informes \nsobre altos niveles de expresi\u00f3n, hay una necesidad \nimperiosa de encontrar mecanismos para aumentar \nla expresi\u00f3n de ant\u00edgenos en plantas y permitir su \nproducci\u00f3n comercial en gran escala. Para tal prop\u00f3-sito, una estrategia que se ha seguido \u00faltimamente es la fusi\u00f3n de p\u00e9ptidos antig\u00e9nicos a la prote\u00edna \u00df-glu-curonidasa (GUS), con lo cual la expresi\u00f3n que nor-\nmalmente era de 0.01% a 0.2% puede aumentar hasta 3% del total de la prote\u00edna soluble; tambi\u00e9n se ha empleado la transformaci\u00f3n de las plantas mediante los cloroplastos y se ha publicado que se pueden obte-451 Vet. M\u00e9x., 37 (4) 2006to induce a general immunity, but to in\ufb02  uence in the \ntype of response. Besides, it was recently determined \nthat the DNA of plants possesses immunostimulatory \nsequences, since it was proved that it can activate the \nantigen presenter cells, including dendritic cells, mac-rophages and B cells, reason why they are considered potential adjuvants.\n63 \nBefore any application in great  scale, the biologi-\ncal components derived from plants must comply with \nthe same safety standards and operation that are \nrequired in other production systems. Nevertheless. \nmany traditional medicines are now exempt of these scrutiny and are not required to meet with those stand-ards due to its classi\ufb01  cation as food supplements. Due \nto the diverse environmental concerns on the genetic \nmanipulated organisms that have been expressed by ecological groups that confuse public opinion, it is important that norms exist to regulate this type of organisms. Its convenient to distinguish between true public concerns and the perceived (scienti\ufb01  c and not \nscienti\ufb01  c).\n33 If the derived biological compound of \nplants are potentially harmful, capable of persisting \nin the environment and can accumulate in non-target \norganisms, then adequate measures should be taken.\nA relevant topic of discussion has been the disper-\nsion of transgenic pollen to herbs or related species.68 \nAt the moment, several methods are being researched \nto contain the transgenic, including apomixes, incom-\npatible genomes, germ latency control, suicide genes, \ninfertility barriers, male infertility and maternal heredity.\nAlso, there is concern for the expression of certain \nproteins in transgenic pollen. For example, the obser-\nvation on the toxic effect of the transgenic corn pollen that contains the crystal protein of Bacillus thuringien-\nsis (Bt) in the monarch butter\ufb02  y larvae, which had a \nsigni\ufb01  cant impact in the public opinion, although the \nvali di ty  o f  this  r ese ar c h  has  be e n  q u es ti o n ed  in  sev-eral occasions and the authors had established that \nthe results are not reliable. Another public concern is \nthe presence of genes\u2019 resistance to antibiotics or their products ( that are used as selection markers) in edible parts of genetically modi\ufb01  ed cultures. Nevertheless, \nthere are several alternatives to generate plants with transgenes in their nucleus\n69 or in the chloroplasts70 \nwithout the use of antibiotics. \nBecause of this, it is clear the enormous potential \nin this technology to produce vaccines and pharma-\nceutical  compounds of interest. With the purpose to \nselect the adequate crop for production, it will be nec-essary to consider several factors like levels of produc-tion, storage conditions, costs of establishment and operation, purifying strategies, size of the market, \nenvironmental concerns, public opinion and alterna-tive technologies.ner niveles de expresi\u00f3n de casi 2.5% de la prote\u00edna \ntotal soluble de la planta.\n21\nEn general, los niveles de expresi\u00f3n de las prote\u00ed-\nnas con aplicaci\u00f3n farmac\u00e9utica producidas en plantas \ntransg\u00e9nicas han sido de menos de 1% de la prote\u00edna \nsoluble total. Este l\u00edmite de 1% es importante para \nuna posible aplicaci\u00f3n comercial, para el caso de que la prote\u00edna se deba puri\ufb01  car.\n14 El ant\u00edgeno de super\ufb01  -\ncie del virus de la hepatitis B indujo s\u00f3lo una respuesta \nde bajo nivel en anticuerpos s\u00e9ricos en un estudio con \nvoluntarios humanos, ello re\ufb02  eja quiz\u00e1 el bajo nivel \nde la expresi\u00f3n (1-5 ng/g de peso fresco) en lechuga \ntransg\u00e9nica.46 A u n q u e  l a  p r o t e \u00ed n a  d e  l a  c \u00e1 p s i d e  d e l  \nvirus Norwalk expresada en papa indujo inmuniza-\nci\u00f3n cuando se consumi\u00f3 por v\u00eda oral, los niveles de la \nexpresi\u00f3n fueron bajos para la administraci\u00f3n oral en \ngran escala: 0.37% de prote\u00edna soluble total (PST).38,67 \nEn este sentido, la expresi\u00f3n de los genes que codi\ufb01  ca-\nban para otras prote\u00ednas humanas en plantas transg\u00e9-\nnicas ha sido tambi\u00e9n baja: alb\u00famina s\u00e9rica humana, \n0.020% PST; eritropoyetina, ~0.003% PST; interfer\u00f3n humano-\u00df, < 0.01% PST. \nPerspectivas futuras \nActualmente se sigue trabajando con la mirada puesta \nhacia el futuro.60-62 S e  e s p e r a  n o  s \u00f3 l o  i n d u c i r  u n a  \ninmunidad general, sino tambi\u00e9n in\ufb02  uir en el tipo de \nrespuesta. Aunado a ello, recientemente se determin\u00f3 \nque el ADN de plantas posee secuencias inmunoes-\ntimulatorias, ya que se comprob\u00f3 que puede activar a las c\u00e9lulas presentadoras de ant\u00edgeno, incluyendo c\u00e9lulas dendr\u00edticas, macr\u00f3fagos y c\u00e9lulas B, por lo que se le considera un adyuvante potencial.\n63  \nAntes de cualquier aplicaci\u00f3n en gran escala, los \ncompuestos biol\u00f3gicos derivados de plantas deber\u00e1n \ncumplir con los mismos est\u00e1ndares de seguridad y \nfuncionamiento que son requeridos en otros sistemas de producci\u00f3n. Sin embargo, muchas medicinas tra-dicionales est\u00e1n ahora exentas de tal escrutinio y no se les exige cumplir con esos est\u00e1ndares debido a su \nclasi\ufb01  caci\u00f3n como suplementos alimentarios. Debido \na las diversas preocupaciones ambientales sobre los organismos gen\u00e9ticamente manipulados, que han sido expresadas por grupos ecologistas que confun-den a la opini\u00f3n p\u00fablica, es  importante que exis-tan normas para regular a este tipo de organismos. \nEs conveniente distinguir entre las preocupaciones \np\u00fablicas verdaderas y las percibidas (cient\u00ed\ufb01  cas contra \nno cient\u00ed\ufb01  cas).\n33 Si los compuestos biol\u00f3gicos deriva-\ndos de plantas son potencialmente da\u00f1inos, capaces \nde persistir en el ambiente y se pueden acumular en \norganismos no blanco, entonces deben tomarse las \nmedidas adecuadas. \nUn t\u00f3pico de discusi\u00f3n relevante ha sido la disper-452Acknowledgements\nSpecial thanks to the National Council of Science and \nTechnology (Conacyt) for the \ufb01  nancial support for \nthe G34635B and CO1-24 projects. \nReferenciassi\u00f3n del polen transg\u00e9nico a hierbas o a especies rela-cionadas.\n68 Actualmente se est\u00e1n investigando varios \nm\u00e9todos para contener a los transgenes, incluyendo apomixis, genomas incompatibles, control de la laten-\ncia del germen, genes suicidas, las barreras de inferti-\nlidad, esterilidad masculina y herencia materna. \nHay tambi\u00e9n preocupaci\u00f3n por la expresi\u00f3n de \ndeterminadas prote\u00ednas en polen transg\u00e9nico. Por ejemplo, la observaci\u00f3n del efecto t\u00f3xico del polen de \nma\u00edz transg\u00e9nico que contiene la prote\u00edna cristal de Bacillus thuringiensis (Bt) en las larvas de la mariposa \nmonarca, tuvieron un impacto signi\ufb01  cativo en la opi-\nni\u00f3n p\u00fablica, aunque la validez de este estudio se ha cuestionado en varias ocasiones y los autores hayan establecido que los resultados no son con\ufb01  ables. Otra \npreocupaci\u00f3n p\u00fablica es la presencia de genes de resis-tencia a antibi\u00f3ticos o sus productos (que se utilizan como marcadores de selecci\u00f3n) en partes comestibles de cultivos gen\u00e9ticamente modi\ufb01  cados. Sin embargo, \nexisten varias alternativas para generar plantas con transgenes en sus n\u00facleos\n69 o en los cloroplastos70 sin \nel uso de antibi\u00f3ticos. \nPor lo anterior, queda claro el enorme potencial \nque tiene esta tecnolog\u00eda para producir compuestos \nde inter\u00e9s farmac\u00e9utico y vacunas. Con el \ufb01  n de selec-\nc i o n a r  e l  c u l ti v o  a d e c u a d o  p a ra  l a  p r o d u c c i \u00f3 n ,  s e r\u00e1  necesario considerar diversos factores como niveles de producci\u00f3n, condiciones de almacenamiento, costos \nde establecimiento y operaci\u00f3n, estrategias de puri\ufb01  -\ncaci\u00f3n, tama\u00f1o del mercado, preocupaciones ambien-tales, opini\u00f3n p\u00fablica y tecnolog\u00edas alternas.\nAgradecimientos \nSe agradece al Consejo Nacional de Ciencia y Tec-\nnolog\u00eda, de M\u00e9xico, el \ufb01  nanciamiento al proyecto \nG34635B. 1.\n2.\n3.\n4.\n5.\n6.\n7.\n8.\n9.\n10.\n11.\n12.\n13.\n14.Babiuk LA, Babiuk SL, Loehr BI, van Drunnen S, van \nden Hurk L. Nucleic acid vaccines: research tool or commercial reality. Vaccine 2000;76:1-23.Daniell, H, Streat\ufb01  eld SJ, Wycoff K. Medical molecu-\nlar farming: production of antibodies, biopharmaceu-ticals and edible vaccines in plants. Trends Plant Sci 2001;6:219-226. \nBinnie C, Cossar JD, Stewart DIH. Heterologous bio-\npharmaceutical protein expression in Streptomyces . \nTrends Biotechnol 1997;15:315-320.Birch RG. Plant transformation: Problems and strate-gies for practical application. Ann Rev Plant Physiol Plant Mol Biol 1997;48:297-326.Koprowski H, Yusibov V. The green revolution:plants as heterologous expression vectors. Vaccine;2001:2735-2741.Kaufman PB, Wu W. Gene transfer and expression in plants. In: Kaufman PB, Wu W, editors. Molecular and cellular methods in biology and medicine. Florida, USA:CRC Press, 1995:367-393.Breitler JC, Labeyrie A, Meynard D, Legavre T, Guider-doni E. Ef\ufb01  cient microprojectile  bombardment-medi-\nated transformation of rice using gene cassettes. Theor Appl Genet 2002;104:709-719.Kohli A, Twyman RM, Abranches R, Wegel E, Stoger E, Christou P. Transgenic integration, organization and interaction in plants. Plant Mol Biol 2003;52:247-258. Potenza C, Aleman L, Sengupta-Copalan C. Target-ing transgene expresion in research, agricultural, and environmental applications: promoters used in plant transformation. In vitro Cell Dev Biol 2004;40:1-22.\nWigdorovitz A, Perez-Filgueira DM, Robertson N, Car-rillo C, Sadir AM, Morris TJ et al.  Induction of a pro-\ntective antibody response to foot and mouth disease in mice following oral or parenteral immunization with alfalfa transgenic plants expressing the viral structural protein VP1. Virology 1999;255, 347\u2013353.Sala F, Rigano MM, Barbante A, Basso B, Walmsley AM, Castiglione S. Vaccine antigen production in transgenic plants: strategies, gene constructs and per-spectives. Vaccine 2003;21:803-806.Voinnet O, Rivas S, Mestre P, Baulcombe D. An enhanced transient expression system in plants based on suppression of gene silencing by the p 19 protein of tomato bushy stunt virus. Plant J 2003;33:949-956.Khoudi H, Laberge S, Ferullo JM, Bazin R, Darveau A, Castonguay Y et al Production of a diagnostic mono-\nclonal antibody in perennial alfalfa plants. Biotechnol Bioeng 1999; 64, 135\u2013143.Kusnadi A, Nikolov R, Zivko L, Howard JA. Production and puri\ufb01  cation of recombinant proteins in transgenic plants: practical considerations. Biotechnol Bioeng 1998;56,473\u2013484.Hood EE, Kusnadi A, Nikolov Z, Howard JA. Molecular farming of industrial proteins from transgenic maize. Adv Exp Med Biol 1999;464:127-147.Larrick JW, Ju L, Chen J, Jaiswal S, Wycoff K. Produc-tion of antibodies in transgenic plants. Ress Immunol 1998;149:603-608. Larrick JW, Thomas DW. Producing proteins in transgenic plants and animals. Curr Op Biotechnol 2001;12:411-418.Lamphear BJ, Streat\ufb01  eld SJ, Jilka JM, Brooks CA, \nBarker DK, Turner DD et al. Delivery of subunit vac-\ncines in maize seed. J Control Rel 2002;85:169-180. Staub JM, Garcia B, Graves J, Hajdukiewicz PT, Hunter P, Nehra N et al. High-yield production of a human \ntherapeutic protein in tobacco chloroplasts. Nat Bio-technol 2000;18, 333\u2013338.15.\n16.\n17.\n18.\n19.453 Vet. M\u00e9x., 37 (4) 200620.\n21.\n22.\n23.\n24.\n25.\n26.\n27.\n28.\n29.\n30.\n31.\n32.\n33.\n34.\n35.36.\n37.\n38.\n39.\n40.\n41.\n42.\n43.\n44.\n45.\n46.\n47.\n48.\n49.\n50.De Cosa B, Moar W, Lee SB, Miller M, Daniell H. Over-\nexpression of the Bt cry2Aa2 operon in chloroplasts leads to formation of insecticidal crystals. Nat Biotech-nol 2001;19:71-74.Kang TJ., Loc NH, Jang MO, Jang YS, Kim YS, Seo JE et al. Expression of the B subunit of E. coli  heat-labile \nenterotoxin in tobacco chloroplasts of plants and its \ncharacterization. Transgenic Res 2003;12:683-691.\nZhong GY, Peterson D, Delaney DE, Bailey M, Wichter DR, Register JC et al. Commercial production of apro-\ntinin in transgenic seeds. Mol Breed 1999;5:345-356. Valdes R, Gomez L, Padilla S, Brito J, Reyes B, Alva-rez T et al.  Large puri\ufb01  cation of an antibody directed \nagainst hepatitis B surface antigen from transgenic tobacco plants. Biochem Biophys Res Commun 2003; 308:94-100.Fischer R, Twyman RM, Schillberg S. Production of antibodies in plants and their use for global health. Vaccine 2003;21:820-825.St\u00f6ger E, Vaquero C, Torres E, Sack M, Nicholson L, Drossard J et al. Cereal crops as viable production and \nstorage systems for pharmaceutical scFv antibodies. Plant Mol Biol 2000;42:  583\u2013590.Ma J, Hiatt A, Hein M, Vine ND, Wang F, Stabila P. Generation and assembly of secretory antibodies in plants. Science 1995;268:716\u2013719.Artsaenko O, Kettig B, Fiedler U, Conrad U, D\u00fcring K. Potato tubers as a biofactory for recombinant antibod-ies. Mol Breed 1998;4:313\u2013319.Ma J, Hikmat B, Wycoff K, Vine N, Chargelegue D, Yu L et al. Characterization of a recombinant plant mono-\nclonal secretory antibody and preventive immunother-apy in humans. Nat Med 1998;4:601\u2013606.Zeitlin L, Olmsted SS, Moench TR, Co MS, Marti-nell BJ, Paradkar VM  et al.  A humanized monoclonal \nantibody produced in transgenic plants for immuno-protection of the vagina against genital herpes. Nat Biotechnol 1998;16: 1361\u20131364.De Wilde C, Van Houdt H, de Buck S, Angenon G, de Jaeger G, Depicker A. Plants as bioreactors for protein production: avoiding the problem of transgene silenc-ing. Plant Biol Mol 2000;43:361-376. Cabanes-Macheteau M, Fitchette-Laine AC, Loutelier-Bourchis C, Lange C, Vine ND, Ma JK et al. N-glycosyl-\nation of a mouse IgG expressed in transgenic tobacco plants. Glycobiology 1999;9:365\u2013372.V aquero C, Sack M, Chandler J, Drossard J, Schuster F, Monecke M  et al . Transient expression of a tumor-\nspeci\ufb01  c single-chain fragment and a chimeric anti-\nbody in tobacco leaves. Proc Natl Acad Sci USA 1999; 96:11128\u201311133.Thomas JA. Safety of foods derived from genetically modi\ufb01  ed plants. Tex Med 2003;99:66-69.\nMor TS, Sternfeld M, Arntzen CJ, Mason HS. Expres-sion of recombinant human acetylcholinesterase in transgenic tomato plants. Biotechnol Bioeng 2001;75:259-266.Mason HS, Warzecha H, Mor T, Arntzen CJ. Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine. Trends  Mol  Med \n2002:8:324-329.Haq TA, Mason HS, Clements JD, Arntzen CJ. Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science 1995;268:714\u2013716.Mason, HS Arntzen C. Expression of hepatitis B sur-\nface antigen in transgenic plants. Proc Natl Acad Sci \nUSA 1992;89:11745\u201311749.Mason, HS, Ball JM, Shi JJ, Jiang X, Estes MK, Arntzen CJ. Expression of Norwalk virus capsid protein in trans-genic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci USA 1996;93:5335\u20135340.Mc Garvey PB, Hammond J, Dienelt MM, Hooper DC, Fu ZF, Dietzschold B et al.  Expression of the rabies \nvirus glycoprotein in transgenic tomatoes. Biotechnol-ogy 1995;13:1484\u20131488.Arakawa T, Chong DKX, Langridge WHR. Ef\ufb01  cacy of \na food plant-based oral cholera toxin B subunit vac-cine. Nat Biotechnol 1998;16:292\u2013297.Carrillo C, Wigdorovitz A, Oliveros JC, Zamorano PI, Sadir AM, Gomez N et al.  Protective immune response \nto foot-and-mouth disease virus with VP1 expressed in transgenic plants. J. Virol. 1998;72:1688\u20131690.Gomez N, Carrillo C, Parra F, Salinas J, Borca MV, Escribano JM. Expression of immunogenic glyco-protein S polypeptides from transmissible gastro-enteritis coronavirus in transgenic plants. Virology 1998;249:352\u2013358.Mason, H.S, Haq TA, Clements JD, Arntzen CJ. Edible vaccine protects mice against Escherichia coli  heat-labile \nenterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine 1998;16:1336\u20131343.Thanavala Y, Wang YF, Lyons P, Mason HS, Arntzen CJ. Immunogenicity of transgenic plant-derived hepatitis B surface antigen. Proc Natl Acad Sci USA 1995; 92: 3358\u20133361.Tacket CO, Mason HS, Losonky G, Clements JD, Levine MM, Arntzen CJ.  Immunogenicity in humans of a recombinant bacterial antigen delivered in a trans-genic potato. Nat Med 1998;4:607\u2013609.Kapusta J, Modelska A, Figlerowicz M, Pniewski T, Letellier M, Lisowa O et al. A plant-derived edible vac-\ncine against hepatitis B virus. FASEB J. 1999;13:1796\u20131799.Castanon S, Marin MS, Martin-Alonso JM, Boga JA, Casals R, Humara JM, et al.  Immunization with potato \nplants expressing VP60 protein protects against rabbit hemorrhagic disease virus. J. Virol 1999; 73: 4452\u20134455.Tuboly T, Yu W, Bailey A, Degrandis S, Du S, Erickson L, et al.  Immunogenicity of  porcine transmissible gas-\ntroenteritis virus spike protein expressed in plants. \nVaccine 2000;18: 2023\u20132028.\nStreat\ufb01  eld SJ, Jilka JM, Hood EE, Turner DD, Bailey \nME, Mayor JM et al.  Plant-based vaccines: unique \nadvantages. Vaccine 2001;19:2742\u20132748.Yusibov V, Hooper DC, Spitsin SV, Fleysh N, Kean RB, Mikheeva T et al.  Expression in plants and immuno-454genicity of plant virus-based experimental rabies vac-\ncine. Vaccine 2002;20:3155-3164.Bonetta L. Edible vaccines:not quite ready for prime time. Nat  Med 2002;8:94.Plana-Duran J, Bastons M, Rodr\u00edguez MJ, Climent I, Co rtes  E,  V e la  C  et al.  Oral  imm uniza ti o n  o f  ra b b i ts  \nwith VP60 particles confers protection against rabbit \nhemorrhagic disease. Arch Virol 1996;141:1423-1436. \nKhandelwal A, Sita SG, Shaila MS. Expression of hem-agglutinin protein of rinderpest virus in transgenic tobacco and immunogenicity of plant-derived protein  \nin a mouse model. Virology 2003;308:207-215.Dos Santos MJ, Wigdorovitz A, Trono K, Rios RD, Fran-zone PM, Gil F et al.  A novel methodology to develop a \nfoot and mouth disease virus (FMDV) peptide-based vaccine in transgenic plants. Vaccine 2002;20:1141-1147.Rossi L, Baldi A, Dell\u2019Orto V, Fogher C. Antigenic recombinant proteins expressed in tobacco seeds as a model for edible vaccines against swine oedema. Vet Res Comm 2003; S27:659-661. Dalsgaard K, Uttenthal A, Jones TD, Xu F, Merry-weather A, Hamilton WDC et al.  Plant-derived vaccine \nprotects target animals against a viral disease. Nat Bio-technol 1997;15:248-252.Nicholas BL, Brennan FR, Martinez-Torrescuadra JL, Casal JI, Hamilton WD, Wakelin D. Characterization of the immune response to canine parvovirus induced by vaccination with chimaeric plant viruses. Vaccine 2002;20:2727-2734. Modelska A, Dietzschold B, Fleysh N, Fu ZF, Steplewski K, Hooper C et al.  Imm unization against rabies wi th \nplant-derived antigen. Proc Natl Acad Sci USA 1998;95:2481-2485. Loza-Rubio E, Saucedo LJ, Aguirre O, Olivera FMT, Gomez-Lim MA. Rabies vaccine expressed in trans-genic maize plants: Construction of vectors. 12th Annual Rabies in the Americas Conference; 2001 November 12-16; Peterborough (ON), Canada, Ontario): WHO,CDC,SSA, 2001:64. Alonso LCC, Scharton TM, Viera LZ, Wysocka M, Trinchieri G, Scott P. The adjuvant effect of interleu-kin-12 in a vaccine against Leishmania major. Science 1994;263: 235-237.Noguchi Y, Richards, EC Chen, YT Old LJ. In\ufb02  uence \nof interleukin-12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA 1995;92: 2219-2223.Bokaya PN, Marinaro MR, Jackson RJ, Menon S, Kiyono Jirillo, E. et al.  II-12 is an effective adjuvant for induc-\ntion of mucosal immunity. J  Immunol 1999;162:122-128.W a n g  Y ,  W a n g  W ,  L i  N ,  Y u  Y ,  C a o  X .  A c t i v a t i o n  o f  \nantigen-presenting cells by immunostimulatory plant \nDNA: a natural resource for potencial adjuvant. Vac-cine 2002;20:2764-2771.Arakawa T, Chong DKX, Merrit JL, Langridge WHR.Expression of cholera toxin B subunit oligomers in transgenic potato plants. Transgenic Res 1997;6:403\u2013413.Richter LJ, Thanavala Y, Arntzen CJ, Mason HS. Produc-\ntion of hepatitis B surface antigen in transgenic plants for oral immunization. Nat Biotechnol 2000;18:1167\u20131171. Tackaberry ES, Dudani AK, Prior F, Tocchi M, Sardana R, Altosaar I  et al.  Development of biopharmaceuticals \nin plant expression systems: cloning, expression and \nimmunological reactivity of human cytomegalovirus \nglycoprotein B (UL55) in seeds of transgenic tobacco. Vaccine 1999;17:3020\u20133029.Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis 2000;182:302\u2013305.Daniell H. GM crops: public perception and scienti\ufb01  c \nsolutions. Trends Plant Sci 1999;4: 467\u2013469.Puchta, H. Removing selectable marker genes: taking the shortcut. Trends Plant Sci. 2000;5:273\u2013274.Ma J, Hiatt A, Hein M, Vine ND, Wang F, Stabila P. Gen-eration and assembly of secretory antibodies in plants. Science 1995; 268: 716\u2013719.Ma J, Hikmat B, Wycoff K, Vine N, Chargelegue D, Yu L, et al. Characterization of a recombinant plant mono-\nclonal secretory antibody and preventive immunother-apy in humans. Nat. Med 1998;4:601\u2013606.Mc Cormick AA, Kumagai MH, Hanley K, Turpen TH, Hakim I, Grill LK et al. Rapid production of speci\ufb01  c vac-\ncines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. PNAS USA 1999;96:703-708.Bouquin T, Thomsen M, Green TH, Mundy J, Hanefeld Dziegiel M. Human anti-rhesus D IgG1 antibody pro-duced in transgenic plants. Transgenic Res 2002;11:115-122.Ko O, Tekoah Y, Rudd PM, Harvey DJ, Dwek RA, Spitsin S et al. Function and glycosilation of plant-derived anti-\nviral monoclonal antibody. PNAS USA 2003;100:8013-8018. Bouche FB, Marquet-Blouin E, Yanagi Y, Steinmetz A, Muller CP . Neutralising immunogenicity of a poly-epitope antigen expressed in a transgenic food plant: a novel antigen to protect against measles. Vaccine 2003;21:2065-2072.Azhar AM, Singh S, Kumar PA, Bhatnagar R. Expres-sion of protective antigen in transgenic plants: a step towards edible vaccine against anthrax. Biochem Bio-phys Res Commun 2002;299:345-351. Giddings G, Allison G, Brooks D, Carter A. Transgenic plants as factories for biopharmaceuticals. Nat Biotech-nol 2000;18:1151\u20131155.Sandhu JS, Krasnyanski SF, Domier LL, Korban SS, Osadjan MD, Buetow DE. Oral immunization of mice with transgenic tomato fruit expressing respiratory \nsincytial virus-F protein induces a systemic immune \nresponse. Transgenic Res 2000;9:127-135. Warzecha H, Mason HS, Lane C, Tryggvesson A, Rybicki E, Williamson AL et al. Oral immunogenicity \nof human papillomavirus-like particles expressed in potato. J Virol;2003:8702-8711. Biemelt S, Sonnewald U, Galmbacher P, Willmitzer L, 51.\n52.\n53.\n54.\n55.\n56.\n57.\n58.\n59.\n60.\n61.\n62.\n63.\n64.65.\n66.\n67.\n68.\n69.\n70.\n71.\n72.\n73.\n74.\n75.\n76.\n77.\n78.\n79.\n80.455 Vet. M\u00e9x., 37 (4) 2006Muller M. Production of human papillomavirus type \n16 virus-like particles in transgenic plants. J Virol 2003;77:9211-9220.Varsani A, Williamson AL, Rose RC, Jaffer M, Rybicki EP. Expression of human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum  cv. \nXanthi. Arch Virol 2003;148:1771-1786.\nWu L, Li JT, Mou ZR, Fei L, Ni B, Geng M et al. Oral \nimmunization with rotavirus VP7 expressed in trans-\ngenic potatoes induced high titers of mucosal neutral-izing IgA. Virology 2003;313:337-342. Martin-Alonso JM, Castanon S, Alonso P, Parra F, Ordas R. Oral immunization using tuber extracts from transgenic potato plants expressing rabbit hem-orrhagic disease virus capsid protein. Transgenic Res 2003;12:127-130.Wu L, Jiang L, Zhou Z, Fan J, Zhang Q, Zhu Q et al.  \nExpression of foot and mouth disease virus epit-81.\n82.\n83.\n84.85.\n86.\n87.\n88.opes in tobacco mosaic virus-based vector. Vaccine \n2003;21:4390-4398.Giddings G, Allison G, Brooks D, Carter A. Transgenic plants as factories for biopharmaceuticals. Nat Biotech-nol 2000;18:1151\u20131155.Ruggiero F, Exposito JY, Bournat P, Gruber V, Perret S, Comte J et al.  Triple helix assembly and processing \no f  h u m a n  c o l l a g e n  p r o d u c e d  i n  t r a n s g e n i c  t o b a c c o  \nplants. FEBS Lett 2000;469:132\u2013136.Chong DK, Langridge WH. Expression of full length bioactive antimicrobial human lactoferrin in potato plants. Transgenic Res 2000; 9: 71\u201378.Gutierrez OA, Avila MF, Saucedo ALJ, Sanchez TC, Gomez-Lim MA. Expression of a single-chain human interleukin-12 gene in transgenic tobacco plants and functional studies. Biotechnol Bioeng 2004;85:734-740.", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}